{
    "ticker": "APVO",
    "name": "Aptevo Therapeutics Inc.",
    "description": "Aptevo Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Founded in 2016 and located in Seattle, Washington, Aptevo specializes in the research and development of novel biologics for the treatment of cancer and other diseases. The company is known for its proprietary technology platform, which enables the creation of differentiated antibody therapeutics with enhanced efficacy and safety profiles. Aptevo's pipeline includes several promising candidates, such as APVO436, a bispecific T-cell engager designed to target cancer cells while activating the body's immune system. The company is dedicated to advancing its therapeutics through clinical trials and collaborations with other biotech and pharmaceutical firms. With a strong commitment to scientific innovation and patient care, Aptevo aims to provide new treatment options for patients with unmet medical needs while ensuring the highest standards of ethical research and development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2016",
    "website": "https://www.aptevotherapeutics.com",
    "ceo": "Marvin L. White",
    "social_media": {
        "twitter": "https://twitter.com/aptevotherapeutics",
        "linkedin": "https://www.linkedin.com/company/aptevo-therapeutics/"
    },
    "investor_relations": "https://ir.aptevotherapeutics.com",
    "key_executives": [
        {
            "name": "Marvin L. White",
            "position": "CEO"
        },
        {
            "name": "Michael A. McNulty",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "APVO436"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aptevo Therapeutics Inc. | Innovative Biologics for Serious Diseases",
        "meta_description": "Learn about Aptevo Therapeutics, a biotechnology company developing innovative therapies for cancer and other diseases. Explore their advanced pipeline and commitment to patient care.",
        "keywords": [
            "Aptevo Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "Innovative Therapies",
            "APVO436"
        ]
    },
    "faq": [
        {
            "question": "What does Aptevo Therapeutics specialize in?",
            "answer": "Aptevo Therapeutics specializes in developing innovative therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Aptevo Therapeutics?",
            "answer": "Marvin L. White is the CEO of Aptevo Therapeutics Inc."
        },
        {
            "question": "Where is Aptevo Therapeutics headquartered?",
            "answer": "Aptevo Therapeutics is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What are Aptevo's main products?",
            "answer": "Aptevo's main product in development is APVO436, a bispecific T-cell engager for cancer treatment."
        },
        {
            "question": "When was Aptevo Therapeutics founded?",
            "answer": "Aptevo Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "NVS"
    ],
    "related_stocks": [
        "MRNA",
        "GILD",
        "VRTX",
        "ABBV"
    ]
}